Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.
NCT ID: NCT06144723
Last Updated: 2023-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1/PHASE2
402 participants
INTERVENTIONAL
2024-03-01
2027-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HS-20105 Phase Ia (Dose escalation)
Patients with advanced solid tumors will be enrolled and receive HS-20105 of various dose strengths until the end of the study in the absence of unacceptable toxicities and disease progression.
HS-20105
Administered intravenously every 21 days.
HS-20105 Phase Ib (Dose expansion)
Depending on data obtained from the dose escalation, dose expansion may proceed with multiple cohorts in subjects with advanced solid tumors. Patients enrolled will receive HS-20105 until the end of the study in the absence of unacceptable toxicities and disease progression. The recommended doses from the dose escalation will be further explored.
HS-20105
Administered intravenously every 21 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HS-20105
Administered intravenously every 21 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Advanced solid tumor patients confirmed by histology or cytology for who that standard treatment is failed or intolerable.
* Patients have at least one target lesion according to RECEST 1.1. The requirements for target lesions are: measurable lesions without local treatment such as irradiation, or with definite progress after local treatment, with the longest diameter ≥ 10 mm in the baseline period (in case of lymph nodes, the shortest axis ≥ 15 mm is required). Patients with only brain and/or bone lesions as target lesions will not be included.
* Fresh or archived tumor tissue samples need to be provided (fresh samples are preferred, and tumor tissue samples within 2 years before the first administration can be accepted; the sample type is formalin fixed, paraffin embedded \[FFPE\] tumor tissue block or FFPE slides).
* ECOG performance status was 0-1 and did not deteriorate in the previous 2 weeks.
* Estimated life expectancy greater than (\>) 12 weeks.
* Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit.
* Females must have the evidence of non-childbearing potential.
* Sign informed consent form.
Exclusion Criteria
1. Previously or current treatment with drugs targeting Trop-2 or other ADC drugs conjugated with HS-9265;
2. Received traditional Chinese medicine therapy with anti-tumor indications within 2 weeks prior to the first administration of HS-20105;
3. Received cytotoxic chemotherapy drugs or other anti-tumor system therapies (including endocrine therapy, molecular targeted therapy, or biological therapy) within 3 weeks prior to the first administration of HS-20105;
4. Received macromolecular anti-tumor drugs or experimental drug therapy within 4 weeks before the first administration of HS-20105;
5. Received local radiotherapy within 2 weeks before the first administration of HS-20105; Received more than 30% of bone marrow irradiation or extensive radiation therapy within 4 weeks before the first administration of HS-20105;
6. Received major surgery within 4 weeks before the first administration of HS-20105.
7. Received strong inhibitors or inducers of CYP3A4, CYP2D6, P-gp or BCRP, or drugs with narrow treatment windows for CYP3A4, CYP2D6, P-gp or BCRP sensitive substrates, have been used.
8. Receiving medication that is known to prolong the QT interval or may lead to torsade de pointes.
* Existing abnormal CTCAE ≥ grade 2 resulted from previous treatment.
* History of other malignancy.
* Uncontrolled pleural, ascites or pericardial effusion.
* Known and unstable central nervous system metastases.
* Inadequate bone marrow reserve or serious organ dysfunction.
* Severe, uncontrolled, or active cardiovascular disease.
* Severe or poorly controlled diabetes.
* Severe or poorly controlled hypertension.
* Clinically significant bleeding symptoms within 1 month before the first administration of HS-20105.
* Serious thrombosis events within 3 months before the first administration of HS-20105.
* Serious infection within 4 weeks before the first administration of HS-20105.
* Received continuous glucocorticoid treatment for more than 7 days within 28 days before the first administration of HS-20105.
* Active infectious disease.
* Hepatic encephalopathy, hepatorenal syndrome, or ≥ Child-Pugh B-grade cirrhosis.
* Serious or uncontrolled eye disease.
* Moderate to severe lung diseases that may interfere with the detection or management of drug-related pulmonary toxicity and seriously affect respiratory function.
* Severe neurological or mental disorders that can interfere with assessment.
* Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study.
* History of hypersensitivity to any active or inactive ingredient of HS-20105.
* The subject who is unlikely to comply with study procedures, restrictions, or requirements, judged by the investigator
* The subject whose safety cannot be ensured or study assessments would be interfered, judged by the investigator.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hansoh BioMedical R&D Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HS-20105-101
Identifier Type: -
Identifier Source: org_study_id